Seroprevalence of SARS-CoV-2-specific Antibodies and Vaccination-related Adverse Events in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Overview

Journal Biomed Pharmacother

Specialties Biology
General Medicine
Pharmacology

Date 2022 Apr 29

PMID 35486976

Authors

Peng Wang

Jing Ni

Ya-Ya Chu

Qing-Qing Chen

Guo-Cui Wu

Yang Fang

Cong Chen

Ruo-Di Zhang

Ling-Qiong Jiang

Yan Zhao

Xi Fang

Jun He

De-Guang Wang

Gui-Hong Wang

Hai-Feng Pan

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs).

Methods: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA).

Results: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2.

Conclusion: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.

Citing Articles

Safety Profile of SARS-CoV-2 Vaccination in Patients with Lupus Nephritis: A Retrospective Study.

Petrou D, Marinaki S, Kriki P, Flouda S, Venetsanopoulou A, Voulgari P J Clin Med. 2025; 14(2.

PMID: 39860412 PMC: 11765568. DOI: 10.3390/jcm14020406.

Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies.

Li X, Li Y, Huang C, Liu J, Liu R, Zhang Z Ann Med. 2024; 56(1):2392882.

PMID: 39155852 PMC: 11334742. DOI: 10.1080/07853890.2024.2392882.

Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection.

Zhang X, Li Y, Dai C, Chu Y, Luan C, Wang G Rheumatol Ther. 2024; 11(1):191-200.

PMID: 38175331 PMC: 10796895. DOI: 10.1007/s40744-023-00630-5.

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.

Guo Y, Cao X, Yang H, Zhou M, Yu B J Glob Health. 2023; 13:06008.

PMID: 36757823 PMC: 9910561. DOI: 10.7189/jogh.13.06008.

References

Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X . Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(16):2255-2258. PMC: 7197626. DOI: 10.1093/cid/ciaa489. View

Fernandez-Ruiz R, Masson M, Kim M, Myers B, Haberman R, Castillo R . Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020; 72(12):1971-1980. PMC: 7941257. DOI: 10.1002/art.41450. View

Picchianti-Diamanti A, Aiello A, Lagana B, Agrati C, Castilletti C, Meschi S . ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. Front Immunol. 2021; 12:740249. PMC: 8477040. DOI: 10.3389/fimmu.2021.740249. View

Li X, Tong X, Yeung W, Kuan P, Yum S, Chui C . Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2021; 81(4):564-568. PMC: 8550868. DOI: 10.1136/annrheumdis-2021-221571. View

Rogerson S, Beeson J, Laman M, Poespoprodjo J, William T, Simpson J . Identifying and combating the impacts of COVID-19 on malaria. BMC Med. 2020; 18(1):239. PMC: 7391033. DOI: 10.1186/s12916-020-01710-x. View

Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C . Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Rev Vaccines. 2020; 19(10):919-936. DOI: 10.1080/14760584.2020.1825951. View

Izmirly P, Kim M, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine K . Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol. 2021; 74(2):284-294. PMC: 8426963. DOI: 10.1002/art.41937. View

Wu J, Leung K, Leung G . Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; 395(10225):689-697. PMC: 7159271. DOI: 10.1016/S0140-6736(20)30260-9. View

Moyon Q, Sterlin D, Miyara M, Anna F, Mathian A, Lhote R . BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2021; 81(4):575-583. PMC: 8494536. DOI: 10.1136/annrheumdis-2021-221097. View

10.

Favalli E, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R . COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev. 2020; 19(5):102523. PMC: 7102591. DOI: 10.1016/j.autrev.2020.102523. View

11.

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

12.

Iyer A, Jones F, Nodoushani A, Kelly M, Becker M, Slater D . Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020; 5(52). PMC: 7857394. DOI: 10.1126/sciimmunol.abe0367. View

13.

Ostuzzi G, Papola D, Gastaldon C, Schoretsanitis G, Bertolini F, Amaddeo F . Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med. 2020; 18(1):215. PMC: 7360478. DOI: 10.1186/s12916-020-01685-9. View

14.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

15.

Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T . Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. 2020; 158(1):97-105. PMC: 7158802. DOI: 10.1016/j.chest.2020.04.010. View

16.

Carmo R, Nunes B, Machado M, Armstrong A, Souza C . Expansion of COVID-19 within Brazil: the importance of highways. J Travel Med. 2020; 27(5). PMC: 7337758. DOI: 10.1093/jtm/taaa106. View

17.

Awadasseid A, Wu Y, Tanaka Y, Zhang W . Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021; 17(1):8-19. PMC: 7757035. DOI: 10.7150/ijbs.52569. View

18.

Gladman D, Ibanez D, Urowitz M . Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2):288-91. View

19.

Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020; 79(7):859-866. PMC: 7299648. DOI: 10.1136/annrheumdis-2020-217871. View

20.

Zhang Y, Xu J, Li H, Cao B . A Novel Coronavirus (COVID-19) Outbreak: A Call for Action. Chest. 2020; 157(4):e99-e101. PMC: 7130311. DOI: 10.1016/j.chest.2020.02.014. View